Intersect ENT's Sinuva drug device. Photo: Intersect ENT

The federal government is holding public meetings next week to decide whether to create new Medicare billing code for 42 drugs and devices.

Why it matters: Many mundane Medicare policies and regulations, like new billing codes, are carried out under the radar. But those policies affect billions of dollars, and one company is already feeling a negative effect from a potentially adverse Medicare ruling.

The details: Several drug and medical device companies submitted applications to the Centers for Medicare & Medicaid Services so their products can get a Medicare billing code — and they can get paid when those products are used.

  • The public agendas show CMS is rubber-stamping almost all of the applications for new permanent codes.

Yes, but: There's one major exception. CMS won't assign a new code to Sinuva, a sinus drug implant made by Intersect ENT, according to a preliminary decision.

  • Intersect ENT's stock price fell by more than 10% Monday, equating to a market cap loss of $130 million.
  • Wall Street analysts believe it is a "clerical error" and will change after company executives meet with federal officials next week.
  • Final decisions come in November, so there's still plenty of time for lobbying and persuasion.

The big picture: This is the busy part of Medicare regulation season. The feds just released proposed rules and payment rates for inpatient hospitals and other facilities that treat seniors. In addition to these new code rulings, look out for new Medicare rules for physicians, hospital outpatients and surgery centers.

Go deeper

BodyArmor takes aim at Gatorade's sports drink dominance

Illustration: Eniola Odetunde/Axios

BodyArmor is making noise in the sports drink market, announcing seven new athlete partnerships last week, including Christian McCaffrey, Sabrina Ionescu and Ronald Acuña Jr.

Why it matters: It wants to market itself as a worthy challenger to the throne that Gatorade has occupied for nearly six decades.

S&P 500's historic rebound leaves investors divided on future

Data: Money.net; Chart: Axios Visuals

The S&P 500 nearly closed at an all-time high on Wednesday and remains poised to go from peak to trough to peak in less than half a year.

By the numbers: Since hitting its low on March 23, the S&P has risen about 50%, with more than 40 of its members doubling, according to Bloomberg. The $12 trillion dollars of share value that vanished in late March has almost completely returned.

Newsrooms abandoned as pandemic drags on

Illustration: Sarah Grillo/Axios

Facing enormous financial pressure and uncertainty around reopenings, media companies are giving up on their years-long building leases for more permanent work-from-home structures. Others are letting employees work remotely for the foreseeable future.

Why it matters: Real estate is often the most expensive asset that media companies own. And for companies that don't own their space, it's often the biggest expense.